Lantern Pharma is at the forefront of transforming oncology drug development through its innovative use of artificial intelligence (AI), machine learning, and genomics. The company has developed a proprietary platform known as RADR® (Response Algorithm for Drug Positioning & Rescue), which integrates data analytics, experimental biology, and machine learning to enhance the drug discovery process. This platform is designed to predict patient responses to various oncology treatments, enabling the identification of effective drug candidates and the stratification of patients into responders and non-responders. By leveraging over 100 billion data points from diverse sources, RADR® facilitates the discovery of new biomarkers and therapeutic indications, ultimately aiming to personalize cancer treatments and improve clinical trial outcomes.

In addition to its AI-driven platform, Lantern Pharma actively manages a robust patent portfolio that underscores its commitment to precision oncology. The company focuses on developing novel small molecule compounds and targeted therapies for specific patient populations, particularly those with rare cancer types. Through its innovative approach, Lantern Pharma aims to reduce the costs and timelines associated with drug development while increasing the likelihood of successful FDA approvals. The integration of advanced machine learning techniques and comprehensive data analysis positions Lantern Pharma as a leader in the quest for effective cancer therapies, addressing the significant challenges faced in the oncology drug development landscape.

United States

Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Cancer

Lantern Pharma

Castration-resistant prostate cancer

LP-100 or 6-hydroxymethylacylfulvene exploits cancer cells’ deficiency &nbsp;in DNA repair mechanisms. LP-100 shows multiple cytotoxic effects on &nbsp;tumor cell biology such as DNA adduct formation, RNA polymerase stalling &nbsp;and redox protein modification. It demonstrates enhanced sensitivity in &nbsp;DNA repair deficient (e.g. ERCC3 mutant or knockout) in vitro and in &nbsp;vivo models. LP-100 leads to rapid inhibition of DNA synthesis and &nbsp;induction of DNA damage. LP-100 is a monofunctional covalent DNA binder &nbsp;that inhibits DNA synthesis and replication, affects cell cycle and &nbsp;induces apoptosis. DNA repair of LP-100-induced lesions is mediated by &nbsp;components of the transcription-coupled nucleotide excision repair &nbsp;(TC-NER) pathway. LP-100 produces damage to DNA that can only be &nbsp;repaired by the TC-NER pathway.
<a href="https://www.lanternpharma.com/pipeline/">Source</a>

LP-100 (Irofulven)

Non-small cell lung carcinoma

LP-300, or Disodium 2,2’-dithio-bis-ethane sulfonate, is a small &nbsp;molecule entity with cysteine modifying activity on select proteins. &nbsp;LP-300 works to modulate multiple cellular pathways simultaneously and &nbsp;is a potential first-in-class combination agent indicated in &nbsp;NSCLC.LP-300 shows cysteine modifying activity on select proteins (ALK), &nbsp;and has shown that it modulates protein function (EGFR, MET, and ROS1). &nbsp;It also acts as a chemo-sensitizer for combination therapies by &nbsp;inactivating proteins that are modulating cellular redox status and drug &nbsp;resistance (TRX, GRX) and possesses chemoprotectant activity that &nbsp;reduces toxicities associated with Taxane / Platinum based &nbsp;chemotherapies.
<a href="https://www.lanternpharma.com/pipeline/">Source</a>

LP-300

Central nervous system illness

Solid tumor/s

LP-184 is a unique small molecule that utilizes its powerful mechanism of action known as synthetic lethality to exploit common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. The anti-tumor potential of LP-184 has been demonstrated across an extensive number of in-vitro and in-vivo cancer models, including pancreatic, bladder, triple-negative breast cancer (TNBC), glioblastoma (GBM), brain metastases, and ATRT. In addition to LP-184’s promise as a single agent, its antitumor potency has the potential to be enhanced when used in combination with existing FDA-approved agents and other treatment modalities including spironolactone, PARP inhibitors, and radiation therapy. Results validating LP-184’s anti-tumor potential have been published at leading conferences and journals including, the American Association for Cancer Research annual meeting, the Society for Neuro-Oncology annual meeting, the San Antonio Breast Cancer Symposium, and the Frontiers in Drug Discovery Journal.

LP-184

High-grade Glioma

Mantle cell lymphoma

Non-Hodgkin lymphoma

LP-284’s mechanism of action, synthetic lethality, was demonstrated to be caused by LP-284’s induction of DNA double-strand breaks. Cells treated with LP-284 had significantly increased double-strand DNA breaks when compared to control-treated cells.

Lantern Pharma

Company Details